Arcus biosciences announces new employment inducement grants

Hayward, calif.--( business wire )--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the compensation committee of the company's board of directors granted one new employee options to purchase a total of 1,450 shares of the company's common stock at an exercise price per share of $17.51, which was the closing price on january 9, 2023, and restricted stock units to acquire a total of 725 shares of the company's common stock. the equity awards were granted pursuant to the company's 2020 inducement plan, which was approved by the company's board of directors in january 2020 pursuant to the “inducement exception” under nyse listed company manual rule 303a.08.
RCUS Ratings Summary
RCUS Quant Ranking